Periaqueductal Gray in Pain and Defensive Behavior

Periaqueductal Gray in Pain and Defensive Behavior

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Periaqueductal Gray in Pain and Defensive Behavior</th>
</tr>
<tr>
<td class="label">Column</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Dorsolateral (dlPAG)</td>
<td>Dorsal and lateral</td>
</tr>
<tr>
<td class="label">Lateral (lPAG)</td>
<td>Lateral</td>
</tr>
<tr>
<td class="label">Ventrolateral (vlPAG)</td>
<td>Ventral and medial</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug Class</td>
</tr>
<tr>
<td class="label">Mu-opioid receptors</td>
<td>Opioids</td>
</tr>
<tr>
<td class="label">5-HT1A receptors</td>
<td>SSRIs/SNRIs</td>
</tr>
<tr>
<td class="label">NMDA receptors</td>
<td>Ketamine</td>
</tr>
<tr>
<td class="label">CB1 receptors</td>
<td>Cannabinoids</td>
</tr>
</table>

The periaqueductal gray (PAG) is a midbrain structure surrounding the cerebral aqueduct that serves as the central hub for pain modulation, defensive behaviors, autonomic responses, and emotional states. First described in the 19th century, the PAG has become recognized as the key node in the brain's endogenous opioid system and the interface between cognitive/affective processes and pain perception.

Periaqueductal Gray in Pain and Defensive Behavior

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Periaqueductal Gray in Pain and Defensive Behavior</th>
</tr>
<tr>
<td class="label">Column</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Dorsolateral (dlPAG)</td>
<td>Dorsal and lateral</td>
</tr>
<tr>
<td class="label">Lateral (lPAG)</td>
<td>Lateral</td>
</tr>
<tr>
<td class="label">Ventrolateral (vlPAG)</td>
<td>Ventral and medial</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug Class</td>
</tr>
<tr>
<td class="label">Mu-opioid receptors</td>
<td>Opioids</td>
</tr>
<tr>
<td class="label">5-HT1A receptors</td>
<td>SSRIs/SNRIs</td>
</tr>
<tr>
<td class="label">NMDA receptors</td>
<td>Ketamine</td>
</tr>
<tr>
<td class="label">CB1 receptors</td>
<td>Cannabinoids</td>
</tr>
</table>

The periaqueductal gray (PAG) is a midbrain structure surrounding the cerebral aqueduct that serves as the central hub for pain modulation, defensive behaviors, autonomic responses, and emotional states. First described in the 19th century, the PAG has become recognized as the key node in the brain's endogenous opioid system and the interface between cognitive/affective processes and pain perception.

The PAG receives input from multiple brain regions—including the prefrontal cortex, amygdala, hypothalamus, and spinal cord—and projects to brainstem nuclei that control spinal pain transmission. This descending pathway provides the anatomical substrate for the psychological modulators of pain including expectation, attention, emotion, and placebo effects.

Columnar Organization

The PAG is organized into longitudinal columns, each with distinct connectivity and functions:

Dorsolateral PAG (dlPAG)

The dlPAG is the primary site of opioid-induced analgesia:

• Dense mu-opioid receptor expression
• Receives input from frontal cortex and limbic structures
• Projects to rostroventromedial medulla (RVM) for descending inhibition
• Activation produces analgesia through endogenous opioids
• Linked to active coping strategies (fight-or-flight responses)
• Electrical stimulation produces potent analgesia

Lateral PAG (lPAG)

The lateral column mediates defensive behaviors:

• Essential for escape and avoidance behaviors
• Receives threat-related information from amygdala
• Projects to brainstem motor nuclei for behavioral output
• Associated with vocalization (pain cries, emotional calls)
• Active during learned fear and threat detection
• Involvement in threat assessment and rapid response

Ventrolateral PAG (vlPAG)

The vlPAG integrates pain with autonomic and emotional states:

• Primary output for opioid and placebo analgesia
• Receives input from hypothalamus and limbic structures
• Projects to RVM and spinal cord
• Associated with passive coping (freezing, quiescence)
• Linked to depression-like states
• Autonomic regulation including cardiovascular control
• State-dependent modulation of pain (attention, expectation)

Descending Pain Modulation

The RVM as a Relay

The rostroventromedial medulla (RVM) serves as a critical relay between PAG and spinal cord:

On-cells: Facilitate pain transmission

• Increase dorsal horn neuronal activity
• Release excitatory neurotransmitters (glutamate, substance P)
• Active during hyperalgesia and allodynia

• Inhibit dorsal horn projection neurons
• Activate through endogenous opioids
• Responsible for stimulation-produced analgesia

• Subserve complex integration
• May encode sensory-discriminative aspects

Mechanisms of Descending Inhibition

The descending pathway operates through multiple mechanisms:

Facilitation vs. Inhibition

The PAG-RVM system can either inhibit or facilitate pain:

Facilitation mechanisms:

• Enhanced on-cell activity
• Pro-inflammatory cytokine signaling
• Glial activation in spinal cord
• Long-term potentiation of dorsal horn neurons

• Chronic pain states involve shifts toward facilitation
• Loss of descending inhibition contributes to chronicity
• Opioid-induced hyperalgesia involves paradoxical facilitation

Pain Modulation in Disease

Chronic Pain

PAG dysfunction is implicated in multiple chronic pain conditions:

Migraine:

• PAG activity altered during migraine attacks
• Brainstem pain-modulatory centers involved in migraine chronification
• Triptans may act partially through PAG
• PAG connectivity changes in chronic migraine

• Altered descending inhibition
• Brainstem pain modulation deficits
• Abnormal PAG responses to experimental pain
• Potential targets for neuromodulation

• Impaired descending inhibition
• Altered PAG connectivity with prefrontal cortex
• Increased pain facilitation

Parkinson's Disease Pain

PAG dysfunction contributes to non-motor pain in PD[@osullivan2021]:

• Reduced PAG gray matter volume in PD patients with pain
• Altered functional connectivity between PAG and RVM
• Pain may precede motor symptoms in some cases
• Dopaminergic modulation of pain pathways

Alzheimer's Disease

PAG involvement in AD is emerging:

• PAG atrophy observed in AD patients
• Pain processing altered—may contribute to behavioral symptoms
• Opioid system changes affect pain perception
• Autonomic dysfunction related to PAG

Neuromodulation Approaches

Deep Brain Stimulation

PAG is a target for DBS in intractable pain:

• Effective for failed back surgery syndrome
• Mechanism involves activation of descending inhibition
• Bilateral implantation typically required
• Benefits diminish over time in some patients

Transcranial Magnetic Stimulation

Non-invasive approaches:

• Motor cortex stimulation activates PAG
• Targeting descending pain pathways
• Emerging evidence for chronic pain treatment

Pharmacological Targets

Circuit Mechanisms

Cross-References

• [Pain Pathways](/mechanisms/pain-pathways)
• [Descending Modulation](/mechanisms/descending-modulation)
• [Brain Regions Index](/brain-regions)
• [Cell Types Index](/cell-types)